The Anti-Interleukin 2 Receptor Antibodies

Muna A Alnimri, Flavio Vincenti

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

The anti-interleukin 2 receptor (IL2R) monoclonal antibodies (mAbs) have emerged as the safest category of immunosuppression agents for transplantation. Two mAbs are approved for use in renal transplantation: basiliximab, a chimeric mAb, and daclizumab, a humanized mAb. Both mAbs target the same epitope on the CD25 chain of the IL2R and have similar efficacy and safety profiles. The main mechanism of action of the anti-IL2R mAbs is to modulate IL2R and block binding of IL2 to the high-affinity IL2R on T cells. An unintended effect of the anti-ILR mAbs is depletion of T regulatory cells which also express CD25. The anti-IL2R mAbs are excellent induction agents for renal transplant recipients at low immunologic risk and patients on steroid withdrawal or calcineurin inhibitor sparing regimens.

Original languageEnglish (US)
Title of host publicationImmunotherapy in Transplantation: Principles and Practice
PublisherWiley-Blackwell
Pages378-384
Number of pages7
ISBN (Print)9781405182713
DOIs
StatePublished - Apr 19 2012

Keywords

  • Basiliximab
  • CD25
  • Daclizumab
  • Immunosuppression
  • Induction
  • Interleukin 2
  • Interleukin 2 receptor
  • Monoclonal antibodies
  • Regulatory cells
  • Transplantation

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'The Anti-Interleukin 2 Receptor Antibodies'. Together they form a unique fingerprint.

  • Cite this

    Alnimri, M. A., & Vincenti, F. (2012). The Anti-Interleukin 2 Receptor Antibodies. In Immunotherapy in Transplantation: Principles and Practice (pp. 378-384). Wiley-Blackwell. https://doi.org/10.1002/9781444355628.ch25